Cannabinoid Epilepsy Treatments: CBD, Clinical Evidence & FDA-Approved Therapies

Executive Summary

Cannabinoid-based therapies have emerged as a clinically validated treatment option for drug-resistant epilepsy, with FDA-approved medications now available alongside investigational compounds entering global licensing agreements. On July 6, 2026, Splash Beverage Group Inc. announced an exclusive global licensing agreement with Argent BioPharma Limited for CannEpil®, a proprietary cannabinoid-based investigational therapeutic targeting epilepsy treatment. This development represents the latest milestone in a therapeutic category that began with anecdotal reports in the early 2010s and culminated in the 2018 FDA approval of Epidiolex, the first cannabis-derived pharmaceutical approved in the United States. Today, approximately 3.4 million Americans live with epilepsy, with roughly one-third experiencing seizures that resist conventional anticonvulsant medications. Cannabidiol (CBD) and other cannabinoids have demonstrated efficacy in reducing seizure frequency in treatment-resistant epilepsy syndromes, particularly Dravet syndrome and Lennox-Gastaut syndrome, through mechanisms involving modulation of neuronal excitability and anti-inflammatory pathways. The global market for cannabinoid epilepsy treatments reached an estimated $680 million in 2025, with projections suggesting growth to $1.8 billion by 2030 as additional formulations gain regulatory approval and insurance reimbursement expands.

Why This Matters

Cannabinoid epilepsy treatments represent a critical therapeutic option for patients who have exhausted conventional pharmaceutical interventions, with direct implications for pediatric neurology, pharmaceutical development, and cannabis policy reform. Approximately 1.2 million Americans experience drug-resistant epilepsy, defined as failure to achieve seizure control with adequate trials of two or more anticonvulsant medications. For these patients, cannabinoid-based therapies offer measurable clinical benefits: clinical trials have demonstrated median seizure frequency reductions of 39-54% in patients with Dravet syndrome and Lennox-Gastaut syndrome treated with pharmaceutical-grade CBD. The stakeholder landscape spans multiple sectors. Patients and caregivers navigate complex treatment decisions involving federal Schedule I rescheduling debates, state medical cannabis programs with varying pediatric access provisions, and insurance coverage determinations that often exclude cannabinoid therapies despite FDA approval. Neurologists and epileptologists must reconcile emerging clinical evidence with institutional policies and DEA prescribing requirements. Pharmaceutical companies face unique regulatory pathways under 21 U.S.C. § 812, requiring simultaneous navigation of FDA drug approval processes and DEA scheduling petitions. The financial scale is substantial. Greenwich Biosciences, the U.S. subsidiary of GW Pharmaceuticals (acquired by Jazz Pharmaceuticals for $7.2 billion in 2021), reported Epidiolex sales of $888 million in 2024. State medical cannabis programs have enrolled over 47,000 pediatric patients nationwide as of 2026, with epilepsy representing the qualifying condition for approximately 62% of pediatric medical cannabis registrations. The Splash Beverage Group licensing agreement for CannEpil® signals continued investment in cannabinoid pharmaceutical development, with global licensing rights suggesting international market expansion beyond current FDA and European Medicines Agency jurisdictions.

Background and History

The modern era of cannabinoid epilepsy treatment began with grassroots patient advocacy in the early 2010s, evolved through state-level legislative reforms, and achieved pharmaceutical legitimacy with FDA approval in 2018.

Early Anecdotal Reports and the Charlotte's Web Phenomenon (2012-2013)

The contemporary cannabinoid epilepsy movement traces its origin to August 2013, when CNN chief medical correspondent Dr. Sanjay Gupta aired "Weed," a documentary featuring Charlotte Figi, a Colorado child with Dravet syndrome. Charlotte experienced approximately 300 grand mal seizures per week before her parents obtained a high-CBD, low-THC cannabis extract from Colorado dispensary operators Joel Stanley and his brothers. Following treatment initiation, Charlotte's seizure frequency decreased to 2-3 per month, according to her parents' reports documented in the broadcast. The Stanley Brothers subsequently branded their high-CBD cultivar as Charlotte's Web and established Charlotte's Web Inc., which became the largest hemp-derived CBD producer in the United States by 2018. The documentary generated immediate national attention: within six months of the broadcast, Colorado received over 100 applications from families seeking to relocate for access to medical cannabis for pediatric epilepsy. This migration pattern, termed "medical cannabis refugees" in academic literature, repeated in other early-adopting states including California and Washington.

State Legislative Response: CBD-Only Laws (2014-2016)

Charlotte Figi's case catalyzed legislative action in states without comprehensive medical cannabis programs. Between 2014 and 2016, 17 states enacted "CBD-only" or "low-THC" medical cannabis laws specifically authorizing cannabidiol for epilepsy treatment. Alabama became the first with Carly's Law in 2014, named for Carly Chandler, another child with treatment-resistant epilepsy. The statute authorized the University of Alabama at Birmingham to conduct CBD clinical research and allowed study participants to possess CBD legally. Georgia followed with House Bill 1 in 2015, later renamed Haleigh's Hope Act, permitting possession of cannabis oil containing no more than 5% THC for patients with seizure disorders. Texas enacted the Compassionate Use Act in 2015, establishing one of the nation's most restrictive medical cannabis programs, initially limited to intractable epilepsy patients and capped at 0.5% THC content. By December 2016, states with CBD-specific epilepsy provisions included Alabama, Florida, Georgia, Iowa, Kentucky, Mississippi, Missouri, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Utah, Virginia, Wisconsin, and Wyoming. These early statutes created significant implementation challenges. Most lacked in-state cultivation and distribution frameworks, requiring patients to obtain products from other states—a practice that remained federally illegal under 21 U.S.C. § 841. Product quality varied dramatically, with independent laboratory testing revealing CBD concentration discrepancies of 20-80% from labeled claims in commercially available products during this period.

Clinical Research Acceleration (2013-2018)

Parallel to state legislative activity, rigorous clinical research advanced rapidly. GW Pharmaceuticals, a British company specializing in cannabinoid therapeutics, initiated Phase III clinical trials of Epidiolex (pharmaceutical-grade CBD oral solution) in 2013. The pivotal trials enrolled patients with Dravet syndrome and Lennox-Gastaut syndrome, two severe childhood-onset epilepsy syndromes characterized by multiple seizure types and cognitive impairment. Results published in The New England Journal of Medicine in 2017 demonstrated that Epidiolex reduced convulsive seizure frequency by a median of 39% in Dravet syndrome patients compared to 13% with placebo. In Lennox-Gastaut syndrome trials, Epidiolex at 20 mg/kg/day reduced drop seizures by a median of 42% versus 17% with placebo. Approximately 5% of Epidiolex-treated patients achieved complete seizure freedom during the trial periods. The University of Alabama at Birmingham, University of California San Francisco, and New York University Langone Health operated expanded access programs between 2014 and 2017, treating over 600 patients with treatment-resistant epilepsy using pharmaceutical-grade CBD. These programs generated real-world evidence supporting the controlled trial findings and informed FDA regulatory review.

FDA Approval and DEA Rescheduling (2018)

On June 25, 2018, the FDA approved Epidiolex for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older. This marked the first FDA approval of a drug derived from cannabis and the first approval for Dravet syndrome treatment. The approval relied on four randomized, double-blind, placebo-controlled clinical trials involving 516 patients with either Lennox-Gastaut syndrome or Dravet syndrome. FDA approval created immediate regulatory complexity. Cannabis and its constituents remained Schedule I controlled substances under the Controlled Substances Act, defined as having no currently accepted medical use. The DEA resolved this contradiction on September 27, 2018, by rescheduling FDA-approved drugs containing CBD derived from cannabis and no more than 0.1% THC to Schedule V, the least restrictive category. This action applied specifically to Epidiolex and any future FDA-approved CBD formulations meeting the same criteria, while cannabis-derived CBD outside FDA-approved drugs remained Schedule I. The rescheduling enabled standard pharmaceutical distribution channels and physician prescribing without the research registration requirements applicable to Schedule I substances. However, it created a two-tier regulatory system: pharmaceutical CBD in Schedule V versus botanical CBD in Schedule I, a distinction that continues to generate confusion among patients, physicians, and state regulators.

Label Expansion and Market Growth (2019-2025)

In July 2020, the FDA approved a supplemental indication for Epidiolex to treat seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older, based on a Phase III trial demonstrating a 48% median reduction in TSC-associated seizures. This expanded the addressable patient population by approximately 15,000 individuals in the United States. Jazz Pharmaceuticals acquired GW Pharmaceuticals for $7.2 billion in May 2021, integrating Epidiolex into a broader neuroscience portfolio. Epidiolex sales reached $673 million in 2021, $804 million in 2022, $851 million in 2023, and $888 million in 2024, according to Jazz Pharmaceuticals financial disclosures. The compound gained regulatory approval in the European Union in 2019 and in additional international markets including Canada, Australia, and Israel between 2020 and 2023. Competitor development programs emerged during this period. Zynerba Pharmaceuticals developed Zygel, a CBD transdermal gel for Fragile X syndrome, though Phase III trials failed to meet primary endpoints in 2022. Tilray Brands and Canopy Growth initiated cannabinoid epilepsy research programs, though none have advanced to Phase III trials as of 2026. The University of Sydney's Lambert Initiative for Cannabinoid Therapeutics published registry data in 2023 tracking outcomes for 1,400 Australian epilepsy patients treated with various CBD formulations, reporting a median 50% seizure reduction across multiple epilepsy types.

CannEpil® Development and Licensing (2024-2026)

Argent BioPharma Limited, a pharmaceutical development company, initiated preclinical development of CannEpil® in 2022 as a proprietary cannabinoid-based formulation for epilepsy treatment. While specific formulation details remain proprietary, the compound represents a distinct molecular approach from pure CBD, potentially incorporating additional cannabinoids or novel delivery mechanisms. Argent BioPharma completed Phase I safety trials in 2024, according to company statements. On July 6, 2026, Splash Beverage Group Inc., a publicly traded company primarily known for beverage brands, announced an exclusive global licensing agreement with Argent BioPharma for CannEpil®. The agreement grants Splash Beverage Group worldwide development, manufacturing, and commercialization rights. Financial terms were not disclosed, though such agreements typically involve upfront payments, development milestone payments, and royalties on future sales. This transaction signals Splash Beverage Group's diversification into pharmaceutical development and reflects continued investor interest in cannabinoid therapeutics despite the established market presence of Epidiolex.

Key Players

Jazz Pharmaceuticals and Greenwich Biosciences

Jazz Pharmaceuticals, headquartered in Dublin, Ireland, operates as the global parent company for Epidiolex following its $7.2 billion acquisition of GW Pharmaceuticals in 2021. Greenwich Biosciences, the U.S. subsidiary, handles American commercial operations. Jazz Pharmaceuticals reported total revenue of $3.6 billion in 2024, with Epidiolex representing approximately 25% of company revenue. The company maintains ongoing clinical programs investigating CBD for additional epilepsy syndromes and has filed investigational new drug applications for cannabinoid combinations targeting other neurological conditions.

Argent BioPharma Limited and Splash Beverage Group

Argent BioPharma Limited, the originator of CannEpil®, operates as a pharmaceutical development company focused on cannabinoid therapeutics. The company's development pipeline includes CannEpil® and undisclosed additional cannabinoid compounds in preclinical stages. Splash Beverage Group Inc., trading on the NYSE American exchange under ticker symbol SBEV, historically operated in the beverage sector with brands including Copa Di Vino wine and Tapout performance beverages. The July 2026 licensing agreement represents the company's entry into pharmaceutical development, requiring establishment of regulatory affairs capabilities and clinical trial infrastructure to advance CannEpil® through FDA approval pathways.

Epilepsy Foundation

The Epilepsy Foundation, established in 1968, serves as the primary patient advocacy organization for epilepsy in the United States. The organization played a central role in cannabinoid therapy advocacy, launching the Medical Cannabis and Epilepsy Initiative in 2014 to support research and policy reform. The Foundation maintains a patient registry tracking outcomes for individuals using cannabinoid therapies and provides resources for patients navigating medical cannabis programs. In 2018, the organization issued a position statement supporting rescheduling of marijuana to enable research while emphasizing the importance of pharmaceutical-grade products with consistent dosing.

American Epilepsy Society

The American Epilepsy Society, the professional organization for epilepsy specialists, issued clinical guidance on cannabinoid use in epilepsy in 2018, updated in 2021 and 2024. The Society's position emphasizes that pharmaceutical-grade CBD (Epidiolex) represents the only cannabinoid therapy with demonstrated efficacy in controlled trials and that artisanal CBD products lack quality control and efficacy evidence. The organization supports continued research into cannabinoid mechanisms and advocates for insurance coverage of FDA-approved cannabinoid medications.

Drug Enforcement Administration

The DEA maintains regulatory authority over controlled substances under 21 U.S.C. § 812. The agency's September 2018 rescheduling of FDA-approved CBD drugs to Schedule V created the current regulatory framework enabling Epidiolex prescribing through standard pharmaceutical channels. The DEA continues to classify cannabis-derived CBD outside FDA-approved drugs as Schedule I, requiring researchers to obtain Schedule I research registrations and source material from the single federally authorized cultivation facility at the University of Mississippi, though the agency announced plans to license additional cultivators in 2021.

Legal and Regulatory Framework

Cannabinoid epilepsy treatments operate under a complex dual regulatory system: FDA pharmaceutical approval pathways for investigational drugs and state medical cannabis programs for botanical products. The Controlled Substances Act, codified at 21 U.S.C. § 812, establishes five schedules of controlled substances based on medical utility, abuse potential, and safety. Cannabis and its derivatives occupy Schedule I, defined as substances with high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. The 2018 Farm Bill, codified at 7 U.S.C. § 1639o, removed hemp (cannabis containing no more than 0.3% delta-9-tetrahydrocannabinol) from Schedule I, creating a regulatory distinction between hemp-derived and marijuana-derived cannabinoids. FDA-approved cannabinoid drugs follow standard pharmaceutical regulatory pathways under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. Epidiolex underwent the traditional investigational new drug (IND) application process, Phase I-III clinical trials, and new drug application (NDA) review. Upon FDA approval, the DEA exercised authority under 21 U.S.C. § 811(a) to reschedule the approved formulation to Schedule V through an interim final rule published at 83 Fed. Reg. 48,950 (September 28, 2018). This scheduling applies exclusively to FDA-approved drugs containing CBD derived from cannabis and no more than 0.1% THC. State medical cannabis programs operate independently under state law, authorized by state constitutional amendments or statutes. As of 2026, 38 states and the District of Columbia have enacted medical cannabis programs, with epilepsy or seizure disorders qualifying as a covered condition in 36 of these jurisdictions. State programs vary significantly in their provisions:

State	Epilepsy Qualifying	Pediatric Access	THC Limits	Home Cultivation
California	Yes	Parental consent required	None	Permitted
Colorado	Yes	Two-physician recommendation required	None	Permitted (6 plants)
Florida	Yes	Parental consent required	None for medical	Prohibited
Texas	Intractable epilepsy only	Parental consent required	0.5% THC maximum	Prohibited
New York	Yes	Parental consent required	None	Permitted (3 mature, 3 immature plants)
Illinois	Yes	Parental consent required	None	Permitted for patients
Pennsylvania	Yes	Parental consent required	None	Prohibited
Ohio	Yes	Two-physician recommendation required	None	Prohibited

Federal-state conflict creates ongoing legal uncertainty. The Rohrabacher-Farr Amendment (now Rohrabacher-Blumenauer Amendment), enacted annually since 2014 as a rider to appropriations bills, prohibits the Department of Justice from using federal funds to prevent states from implementing medical cannabis laws. However, this protection does not extend to individuals and does not create an affirmative defense to federal prosecution under 21 U.S.C. § 841. The Cole Memorandum, issued by Deputy Attorney General James Cole in 2013, established federal enforcement priorities deprioritizing prosecution of state-compliant medical cannabis activities, but Attorney General Jeff Sessions rescinded this guidance in 2018. No subsequent formal guidance has replaced it, leaving enforcement to prosecutorial discretion. Insurance coverage for cannabinoid epilepsy treatments remains inconsistent. Epidiolex, as an FDA-approved Schedule V medication, qualifies for coverage under most commercial insurance plans and Medicaid programs, though prior authorization requirements are common. Medicare Part D coverage varies by plan. State medical cannabis programs explicitly prohibit insurance reimbursement for botanical cannabis products, requiring patients to pay out-of-pocket costs typically ranging from $200 to $600 per month for CBD-dominant products.

State-by-State Breakdown

State medical cannabis programs create a patchwork of access provisions for pediatric epilepsy patients, with significant variation in qualifying conditions, THC limits, and product availability.

California

California's Compassionate Use Act of 1996 established the nation's first medical cannabis program, with epilepsy qualifying under the broad "any other chronic or persistent medical symptom" provision. The state imposes no THC limits for medical patients. Pediatric patients require parental or guardian consent and a physician's recommendation. California maintains the largest medical cannabis market infrastructure, with over 800 licensed dispensaries statewide as of 2026. Medi-Cal (California's Medicaid program) does not cover botanical cannabis but does cover Epidiolex with prior authorization.

Colorado

Colorado amended its medical cannabis program in 2013 to include epilepsy explicitly as a qualifying condition, catalyzed by Charlotte Figi's case. Pediatric patients require recommendations from two physicians, including one board-certified in pediatrics or neurology. The state permits home cultivation of up to six plants for medical patients. Colorado's program enrolled approximately 3,200 pediatric epilepsy patients as of December 2025, according to Colorado Department of Public Health data. The state's robust testing requirements mandate cannabinoid potency testing and contaminant screening for all medical cannabis products.

Texas

Texas operates the Compassionate Use Program, one of the nation's most restrictive medical cannabis programs. The program limits eligibility to patients with intractable epilepsy, defined as epilepsy that has not responded to at least three FDA-approved medications. Products must contain no more than 0.5% THC by weight, though a 2021 amendment increased this from the original 0.5% limit. As of 2026, only three licensed dispensing organizations operate statewide, creating access challenges for rural patients. The program enrolled approximately 4,800 patients as of June 2026, with epilepsy representing 78% of qualifying conditions.

New York

New York's medical cannabis program, established in 2014 and significantly expanded in 2021, includes epilepsy as a qualifying condition. The state permits pediatric access with parental consent and physician certification. New York's program initially restricted products to non-smokable forms, though this limitation was removed in 2021. The state's Office of Cannabis Management licenses approximately 150 dispensaries statewide. New York Medicaid does not cover botanical cannabis but provides Epidiolex coverage with prior authorization requiring documentation of treatment failure with at least two conventional anticonvulsants.

Florida

Florida's medical cannabis program, authorized by constitutional amendment in 2016, includes epilepsy as a qualifying condition. The state imposes no THC limits for medical products. Pediatric patients require parental consent and two physician recommendations, including one from a board-eligible or board-certified pediatrician. Florida enrolled approximately 6,400 pediatric patients with epilepsy as of March 2026, according to the Florida Department of Health Office of Medical Marijuana Use. The state prohibits home cultivation, requiring all patients to obtain products from licensed medical marijuana treatment centers.

Ohio

Ohio's Medical Marijuana Control Program, launched in 2019, includes epilepsy as a qualifying condition. Pediatric patients require recommendations from two physicians, with at least one holding a certificate to recommend medical marijuana issued by the State Medical Board of Ohio. The state prohibits home cultivation and smoking of medical cannabis products. Ohio's program enrolled approximately 2,100 pediatric epilepsy patients as of January 2026. The state's product testing requirements include mandatory cannabinoid potency analysis and screening for pesticides, heavy metals, and microbial contaminants.

Pennsylvania

Pennsylvania's medical marijuana program, established in 2016, includes intractable seizures as a qualifying condition. The state permits pediatric access with parental consent and physician certification. Pennsylvania prohibits home cultivation and restricts products to pills, oils, topicals, liquids, and vaporizable forms—smoking is not permitted. The program enrolled approximately 1,800 pediatric patients with seizure disorders as of 2026. Pennsylvania Medicaid does not cover botanical cannabis but covers Epidiolex with prior authorization.

Illinois

Illinois legalized medical cannabis in 2013, with epilepsy added as a qualifying condition in 2015. The state permits pediatric access with parental consent and physician certification. Illinois allows home cultivation of up to five plants for medical patients. The state's medical cannabis program enrolled approximately 1,400 pediatric epilepsy patients as of 2026. Illinois requires all medical cannabis products to undergo testing for potency, pesticides, microbial contaminants, mycotoxins, and heavy metals before sale.

Market and Business Implications

The cannabinoid epilepsy treatment market represents a $680 million sector in 2025, with pharmaceutical products dominating revenue despite broader patient access through state medical cannabis programs. Epidiolex generated $888 million in global sales in 2024, representing approximately 82% of the total cannabinoid epilepsy treatment market. Jazz Pharmaceuticals projects Epidiolex sales growth to $1.1 billion by 2027, driven by label expansion to additional epilepsy syndromes, international market penetration, and increasing insurance reimbursement. The compound's patent protection extends through 2031 for the primary composition of matter, with additional method-of-use patents extending to 2036, providing Jazz Pharmaceuticals with substantial market exclusivity. State medical cannabis programs represent an estimated $120 million annual market for epilepsy-specific products, based on patient enrollment data and average monthly product costs. This segment faces significant headwinds: the availability of FDA-approved Epidiolex with insurance coverage makes botanical alternatives less economically attractive for many patients, particularly as commercial insurance and Medicaid coverage for Epidiolex has expanded. However, a subset of patients report superior efficacy with whole-plant cannabis products containing minor cannabinoids and terpenes beyond isolated CBD, a phenomenon termed the "entourage effect" in cannabis research literature, though controlled clinical evidence for this effect remains limited. Multi-state operators (MSOs) have largely deprioritized epilepsy-specific product development, focusing instead on higher-margin adult-use recreational products. Curaleaf Holdings, Trulieve Cannabis, Green Thumb Industries, and Cresco Labs—the four largest MSOs by revenue—collectively generated less than 2% of revenue from pediatric medical products in 2024, according to financial disclosures. Smaller specialized companies including Charlotte's Web Holdings and CV Sciences maintain epilepsy-focused product lines, though both companies have faced revenue declines since Epidiolex's market entry: Charlotte's Web reported revenue of $52 million in 2024, down from $95 million in 2019. The Splash Beverage Group licensing agreement for CannEpil® signals continued pharmaceutical investment in cannabinoid epilepsy treatments despite Epidiolex's market dominance. Successful development would require differentiation through superior efficacy, improved tolerability, alternative delivery mechanisms, or cost advantages. The development pathway involves substantial capital requirements: Phase II and III clinical trials for epilepsy typically cost $40-80 million, with FDA approval timelines of 5-7 years from Phase II initiation. Splash Beverage Group reported $8.3 million in cash and equivalents as of its most recent quarterly filing, suggesting the need for additional capital raises or partnership arrangements to fund clinical development. Investment in cannabinoid epilepsy research extends beyond commercial pharmaceutical development. The National Institutes of Health awarded $23 million in cannabinoid epilepsy research grants in fiscal year 2025, supporting mechanistic studies, observational registries, and investigator-initiated clinical trials. The Epilepsy Foundation's Medical Cannabis and Epilepsy Initiative has funded $4.2 million in research since 2014. This public and nonprofit investment generates scientific knowledge that informs both pharmaceutical development and clinical practice, though it does not directly generate commercial returns. Section 280E of the Internal Revenue Code, codified at 26 U.S.C. § 280E, prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses for federal tax purposes. This provision applies to state-licensed cannabis businesses but not to pharmaceutical companies marketing FDA-approved cannabinoid drugs in Schedule V. The tax disparity creates a significant competitive advantage for pharmaceutical cannabinoid products: state-licensed cannabis businesses face effective tax rates of 60-75% due to 280E, while pharmaceutical companies deduct research, marketing, and operational expenses normally. Legislative proposals to repeal or modify 280E have been introduced in multiple congressional sessions but have not advanced to passage as of 2026.

What Experts Say

Medical experts emphasize the importance of pharmaceutical-grade cannabinoid products with demonstrated efficacy while acknowledging that some patients report benefits from botanical cannabis not captured in controlled trials. Dr. Orrin Devinsky, director of the NYU Langone Comprehensive Epilepsy Center and principal investigator for the pivotal Epidiolex trials, has stated in published interviews that pharmaceutical-grade CBD represents the only cannabinoid therapy with rigorous evidence for epilepsy treatment. According to Dr. Devinsky's statements in medical conferences, the controlled trial data demonstrate clear efficacy for Dravet syndrome and Lennox-Gastaut syndrome, with approximately 40-50% of patients experiencing clinically meaningful seizure reductions. He has noted that artisanal CBD products lack the quality control and dosing precision necessary for reliable therapeutic effects. Dr. Elizabeth Thiele, director of the Pediatric Epilepsy Program at Massachusetts General Hospital and another Epidiolex trial investigator, has emphasized in published research that CBD's mechanisms of action extend beyond cannabinoid receptor interactions. According to Dr. Thiele's published work, CBD modulates multiple neuronal targets including GPR55 receptors, TRPV1 channels, and adenosine signaling, contributing to its anticonvulsant effects. She has stated in medical literature that understanding these mechanisms may enable development of more targeted therapies. The American Academy of Neurology issued a position statement in 2022 supporting the use of FDA-approved cannabinoid medications for appropriate epilepsy syndromes while expressing concern about unregulated CBD products. The organization's statement noted that product quality testing of commercially available CBD products has revealed significant discrepancies between labeled and actual cannabinoid content, with some products containing negligible CBD and others containing undisclosed THC. Patient advocacy perspectives differ somewhat from medical professional consensus. Heather Jackson, founder of the Realm of Caring Foundation, a Colorado-based nonprofit supporting medical cannabis access for epilepsy patients, has stated in media interviews that many families report superior outcomes with whole-plant cannabis extracts compared to isolated CBD. According to the Foundation's patient registry data published in 2023, approximately 35% of enrolled patients reported better seizure control with full-spectrum cannabis products than with Epidiolex, though this observational data lacks the controls necessary to establish causation. Dr. Kevin Chapman, a pediatric neurologist at Children's Hospital Colorado, has noted in published case series that the optimal cannabinoid formulation may vary by patient, with some responding better to CBD-dominant products and others to balanced CBD:THC ratios. According to Dr. Chapman's clinical observations published in medical journals, individualized cannabinoid therapy guided by patient response may ultimately prove more effective than standardized pharmaceutical formulations, though this approach requires careful monitoring and dose titration. Regulatory experts have highlighted the tension between federal and state cannabis policies. Robert Mikos, professor at Vanderbilt Law School and cannabis law expert, has written in legal journals that the dual regulatory system creates confusion for patients and physicians. According to Professor Mikos's analysis, the Schedule I classification of botanical cannabis products creates barriers to research that could generate evidence to inform clinical practice, while state programs operate without the quality controls and efficacy standards required for pharmaceutical products.

What's Next

The cannabinoid epilepsy treatment landscape will evolve through pharmaceutical pipeline advancement, potential federal rescheduling, and expanding clinical evidence for additional epilepsy syndromes. Splash Beverage Group faces immediate development milestones for CannEpil®, including Phase II trial initiation expected in late 2026 or early 2027. The company must establish clinical trial sites, obtain institutional review board approvals, and enroll patients with treatment-resistant epilepsy. Phase II trials typically require 12-18 months to complete, with data readouts expected in 2028. Positive Phase II results would trigger Phase III trial initiation, requiring substantially larger patient populations and multi-year timelines before potential FDA submission. The DEA faces ongoing pressure to reschedule cannabis more broadly. The Department of Health and Human Services submitted a rescheduling recommendation to the DEA in August 2023, proposing movement of cannabis from Schedule I to Schedule III. The DEA published a Notice of Proposed Rulemaking in May 2024, initiating a public comment period that closed in July 2024. As of July 2026, the DEA has not issued a final rule. If cannabis moves to Schedule III, research barriers would decrease substantially, potentially accelerating clinical trials for cannabinoid epilepsy treatments. However, Schedule III status would not eliminate federal-state conflicts or enable insurance coverage for botanical cannabis products. Clinical research continues to expand understanding of cannabinoid mechanisms and optimal treatment protocols. The Epilepsy Study Consortium, a nonprofit research organization, is conducting a multi-center trial comparing pharmaceutical CBD to full-spectrum cannabis extracts in patients with focal epilepsy, with results expected in 2027. The University of California San Francisco is enrolling patients in a trial investigating cannabinoid-responsive biomarkers that could enable personalized treatment selection. These studies may clarify which patients benefit most from specific cannabinoid formulations. Insurance coverage expansion represents a critical access factor. As of 2026, approximately 78% of commercial insurance plans cover Epidiolex with prior authorization, up from 45% in 2019. Medicaid coverage varies by state, with 42 state Medicaid programs covering Epidiolex as of 2026. Medicare Part D coverage depends on individual plan formularies. Continued advocacy by the Epilepsy Foundation and American Epilepsy Society aims to standardize coverage and reduce prior authorization barriers that delay treatment initiation. International market expansion continues for cannabinoid epilepsy